Highlights  PGP variation was studied in 2 TCBZ resistant and 3 susceptible Latin American isolates  No SNPs in the terminal domain of PGP could be associated with TCBZ resistance  Several variable positions are detected along the 42 Kb of the FhPGP gene  More detailed and extensive efforts are needed to identify markers of resistance ABSTRACT The use of Triclabendazole for controlling fasciolosis is compromised by increased drug resistance affecting livestock and humans. Although the mode of action of TCBZ is still unknown, putative candidates and markers of resistance have been advanced. A single nucleotide polymorphism (T687G) in F. hepatica PGP was proposed as marker of resistance in a small scale study of European susceptible and resistant flukes, but the association was not found in Australian samples. The T687G SNP was absent in more than 40 samples from 2 TCBZ-resistant and 3 susceptible isolates across Latin America here analyzed. While the American samples showed more variable SNPs than the previous ones, none of the SNPs detected showed a marked association with resistance.
Fasciolosis, is arguably one of the most widely distributed zoonotic diseases, with a major impact on livestock resulting in important economic losses estimated at thousands of millions of dollars globally [1] . The increased incidence of human cases has drawn attention to this neglected foodborne disease affecting approximately 50 million people worldwide [2] . In the Americas the disease is widespread in livestock, while is considered an important human foodborne infection in the Altiplano region of Bolivia and Peru [3] .
Triclabendazole (TCBZ) is the drug of choice to combat this parasite based on its broad spectrum of activity against liver fluke of all ages down to 2 days post-infection in the definitive host [4] . However, the effectivity of this benzimidazolic drug has been compromised by reports of TCBZ resistance that first emerged in Australia, and were rapidly followed by cases in Europe, and in South America. More worrying, human cases reluctantly treated with TCBZ have been recently reported in Chile, and Peru (reviewed in [5] .
Investigation of TCBZ resistance in the fluke in laboratories worldwide has resulted in the pursuit of a number of potential candidate genes and biological pathways [4, 5] . The precise loci and, therefore, genes involved are still to be defined but a genome-wide approach is currently underway to identify the major genetic determinant of TCBZ resistance [6] . The increased cellular efflux of TCBZ in F. hepatica is related to ABC transporters as the P-glycoproteins (PGP) [4, 7] . TCBZ-resistant isolates have been shown to process TCBZ more rapidly and their resistant phenotype can be reversed, under in vitro conditions, by the co-administration of inhibitors of P-glycoprotein (PGP) drug efflux pumps or drug detoxification pathways [4, 8] .
A C C E P T E D M A N U S C R I P T
A previous study on European Fasciola isolates suggested that a single nucleotide polymorphism (SNPs) resulting in a PGP point mutation was associated with the resistant phenotype [9]. The same variation was not associated with resistance in Australian isolates [10] . In this study we analyzed the same terminal domain of F. hepatica PGP at the DNA and transcript levels in several samples with different status of resistance obtained from different locations across South America and compared them with those of the previous European and Australian studies. Our dataset consisted of individual flukes from 2 isolates defined as TCBZ-resistant from Bariloche, Argentina (7 samples) [11, 12] and Cajamarca, Peru (10 DNA and 3 cDNA samples) [12,13], 7 flukes from an Argentinian isolate (Cedive, Chascomus) susceptible to TCBZ but resistant to Albendazole (ABZ) [12, 14] . Beside this we included a TCBZ-susceptible isolate from Mexico (6 DNA and 7 cDNA samples), and 13 individuals flukes from field isolates from Catamarca, Argentina whose resistant status is unknown (Suppl. Figure 1 ). As an additional reference for this study, 5 adult flukes of the UK Cullompton susceptible isolate were also analyzed [12] . Considering this study and the two previous ones, the geographical width of the analysis of PGP variation is extended and the total amount of resistant and susceptible worms analyzed is roughly doubled (Suppl. Figure 1 , Table 1 ).
We analyzed 16 variable positions in an amplimer of 830 bp, some of them shared with the previous studies and some novel. Eleven of the variable positions fall within the last intron, and the remaining 5 variable sites on the adjacent regions of the two final exons of PGP (Figure 1 In order to gain further insights we organized the samples into haplotypes according to the various SNPs shared in the region amplified using DnaSP6 [15] . For this, we consider all the variants in the 2 previous studies [9,10] and those here obtained, resulting in 31 different haplotypes ( Table 1) Table 1 A).
Since we have recently performed a transcriptomic analysis of 3 American isolates with different drug susceptibility [16] , we looked at variations detected in the FhPGP gene in this study. We retrieved Contig 2471 where FhPGP is found and all the reads mapped to it from the three isolates, namely Cajamarca, Peru (TCBZR), Cenapa, Mexico Table 2 ). The low amount of samples analyzed do not allow to infer selective presence of SNPs in resistant or susceptible isolates. However, it is worth mention that most variants are shared. These results highlight that sequence variability can be high within F. hepatica as it has been advanced by the genomic studies [17, 18] . Consequently efforts to associate variant sites with particular phenotypes as drug resistance need to be very cautious before reporting.
In conclusion our data confirm that the T687G SNP in the PGP gene alleged as candidate for TCBZ resistance marker [9] is not detected in any of the American sequences analyzed compromising its proposed involvement in TCBZ resistance. Several other variable positions mapping within the last intron can be observed, but there is no evidence of altered splicing that might account for the resistant phenotype according to our RT-PCR experiments. Our study also highlight that the American isolates are slightly more variable at the PGP gene region under study than the European or Australian counterparts. This might be related to the largest dataset here analyzed and the fact that correspond to a widest geographical distribution of the Latin American samples. These results are also consistent with recent descriptions of genetic variability in F. hepatica in general [18] . Interestingly a recent study showed low genetic diversity in Peruvian flukes from Cajamarca wen analyzing mitochondrial ND1 gene and the ribosomal ITS [19] .
While these results compromise the causal role of the previously indicated SNP, they do not exclude PGP as a candidate to resistance. Indeed, the region studied so far represent less than a tenth of the original protein, and our transcriptomic evidence [16] show that much variation exist along the 42 kb of the gene. Furthermore, the genomic sequences of F.hepatica have revealed multiple ABC transporters that might be playing a detoxifying role. The availability of genomic sequences allow now to perform more extensive studies analyzing in parallel variations in several genes across numerous individuals, opening new avenues for investigating variants associated with the resistance of F. hepatica to TCBZ.
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